MedTrace Logo

Miltefosine for Mucosal Leishmaniasis

NCT00373776 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2006-09-08

No results posted yet for this study

Summary

This trial will study miltefosine as a treatment for mucosal leishmaniasis.

Conditions

  • Leishmaniasis

Interventions

DRUG

miltefosine 2.5 mg/kg/day for 28 days

Sponsors & Collaborators

  • AB Foundation

    lead OTHER

Principal Investigators

  • Jaime soto, MD · CIBIC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Completion
2006-05-31

Countries

  • Bolivia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00373776 on ClinicalTrials.gov